Valuation: ANI Pharmaceuticals, Inc.

Market Cap 1.55B 1.37B 1.28B 1.17B 2.2B 149B 2.23B 15.52B 6.02B 76.02B 5.81B 5.68B 244B P/E 2026 *
14.4x
P/E 2027 * 12.7x
Enterprise Value 1.7B 1.51B 1.41B 1.28B 2.42B 163B 2.44B 17.03B 6.6B 83.39B 6.37B 6.23B 268B EV / Sales 2026 *
1.54x
EV / Sales 2027 * 1.2x
Free-Float
86.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.21%
1 week-3.82%
Current month-0.94%
1 month+2.48%
3 months-15.38%
6 months-6.77%
Current year-8.83%
1 week 71.64
Extreme 71.64
74.78
1 month 69.58
Extreme 69.58
79.43
Current year 69.58
Extreme 69.58
87.76
1 year 69.58
Extreme 69.58
97
3 years 48.2
Extreme 48.2
99.5
5 years 22.31
Extreme 22.31
99.5
10 years 22.31
Extreme 22.31
99.5
Manager TitleAgeSince
Chief Executive Officer 48 08/09/2020
Director of Finance/CFO 55 06/05/2016
Compliance Officer - 24/02/2022
Director TitleAgeSince
Chairman 62 24/11/2025
Director/Board Member 68 06/08/2020
Director/Board Member 66 06/08/2020
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26 A Sell

Chief Financial Officer

-2,850 0.0124%
9/15/26 A Sell

Chief Executive Officer

-5,400 0.0235%
9/14/26 A Sell

General Counsel

-500 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-3.82%-21.82%+22.75% 1.55B
+0.28%-3.43%+35.40%+111.31% 1,019B
-1.18%-6.76%+34.75%+61.36% 617B
-0.45%-1.56%+13.88%+77.78% 464B
-3.60%-6.30%+56.90%+34.48% 356B
+0.56%-2.19%+20.53%+40.90% 333B
-0.09%-4.25%+9.87%+33.26% 267B
-1.25%-5.91%-7.64%+7.82% 244B
-1.03%-4.46%+35.82%+50.70% 218B
-0.93%-5.65%+26.44%+92.25% 179B
Average -0.75%-3.43%+20.41%+53.26% 369.87B
Weighted average by Cap. -0.66%-3.54%+28.21%+68.05%

Financials

2026 *2027 *
Net sales 1.1B 981M 916M 835M 1.57B 106B 1.59B 11.08B 4.29B 54.27B 4.15B 4.06B 174B 1.23B 1.09B 1.02B 930M 1.75B 118B 1.77B 12.34B 4.78B 60.45B 4.62B 4.52B 194B
Net income 114M 101M 94.52M 86.15M 162M 10.96B 164M 1.14B 443M 5.6B 428M 419M 17.98B 128M 114M 106M 96.87M 183M 12.32B 184M 1.29B 498M 6.3B 481M 471M 20.21B
Net Debt 150M 133M 124M 113M 214M 14.42B 216M 1.51B 583M 7.37B 563M 551M 23.66B -68.85M -61.17M -57.1M -52.04M -98.15M -6.62B -99.06M -691M -268M -3.38B -259M -253M -10.86B
Logo ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Employees
970
Date Price Change Volume
05/10/26 $71.97 -0.29% 39,565
02/10/26 $72.18 -1.07% 309,509
01/10/26 $72.96 +0.43% 316,691
30/09/26 $72.65 +0.04% 383,955
29/09/26 $72.62 -2.95% 328,842
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
72.18USD
Average target price
105.78USD
Spread / Average Target
+46.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANIP Stock